SC
NMRA icon

Stempoint Capital’s Neumora Therapeutics NMRA Stock Holding History

Stempoint Capital’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-428,137
Closed -$4.54M – 73
2024
Q4 		$4.54M Buy
+428,137
New +$5.13M 1.13% 30

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return

Stempoint Capital's NMRA Position: Q1 2025 in Review

Stempoint Capital sold out of Neumora Therapeutics (NMRA) in Q1 2025, closing a stake of 428,137 shares — an estimated $4.54M sold.

Stempoint Capital first reported a position in NMRA in Q4 2024 and held it in 1 quarter. The position peaked at $4.54M in Q4 2024. 115 funds tracked by Wall St. Rank hold NMRA as of Q1 2025.

  • Stempoint Capital reported no remaining Neumora Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Stempoint Capital sold 428,137 Neumora Therapeutics shares in Q1 2025, an estimated $4.54M.
  • Stempoint Capital first reported a position in Neumora Therapeutics in Q4 2024 and held it in 1 quarter.
  • Stempoint Capital's Neumora Therapeutics position peaked at $4.54M in Q4 2024.
  • 115 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2025.

Based on Stempoint Capital's 13F filing for Q1 2025, filed 15 May 2025.